A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases-Reference-Cited by-同舟云学术

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Published:2020-09-03 Issue:2 Volume:34 Page:252-263
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Huang Richard S. P.,Haberberger James,Severson Eric,Duncan Daniel L.,Hemmerich Amanda,Edgerly Claire,Ferguson Naomi Lynn,Williams Erik^ORCID,Elvin Julia,Vergilio Jo-Anne,Killian Jonathan Keith,Lin Douglas I.,Tse Julie,Hiemenz Matthew,Owens Clarence,Danziger Natalie,Hegde Priti S.,Venstrom Jeffrey,Alexander Brian,Ross Jeffrey S.^ORCID,Ramkissoon Shakti H.

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

https://www.nature.com/articles/s41379-020-00664-y.pdf

Reference45 articles.

1. Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci. 2016;17:1151.

2. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–62.

3. Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist. 2017;22:1392–9.

4. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.

5. Heimes AS, Schmidt M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs. 2019;28:1–5.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers;Cancer Immunology, Immunotherapy;2024-09-05

2. Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer;Frontiers in Pharmacology;2024-07-22

3. Successful pembrolizumab treatment for microsatellite instability-high thymoma: A case report;Respiratory Investigation;2024-07

4. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice;Biomedicine & Pharmacotherapy;2024-06

5. The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations;Gynecologic Oncology;2024-05